Dioseve Inc. Raises $7 Million in Funding Round
July 12, 2024, 9:45 pm
Dioseve Inc., a Tokyo-based company focused on assisted reproductive technology, has successfully raised $7 million in a recent funding round. The funding, led by Spiral Capital and Archetype Ventures, will be used to further research and development efforts and expand the company's global presence. With this latest round, Dioseve has now raised a total of approximately $10 million.
The company's innovative approach involves using iPS cells to develop oocytes for infertility treatments, a process known as the "DIOLs" technology. By introducing specific genes into these cells, Dioseve is able to produce oocytes quickly and cost-effectively, offering a new solution for couples struggling with fertility issues.
Assisted reproductive technology has remained largely unchanged for decades, with options limited and often dependent on individual circumstances. Dioseve's technology aims to provide a more accessible and flexible solution for those facing fertility challenges, giving them the freedom to choose when to start a family without the constraints of age or other factors.
Led by CEO Kazuma Kishida, Dioseve was established in 2021 and has quickly made a name for itself in the field of reproductive medicine. The company's commitment to innovation and accessibility has attracted a diverse group of investors, including ANRI, ASKA Pharmaceutical Co., DG Daiwa Ventures, Future Venture Capital Co., QR Investment, and others.
As Dioseve continues to grow and expand its reach, the company remains dedicated to revolutionizing the field of assisted reproductive technology, offering hope and new possibilities to those struggling to start a family.
The company's innovative approach involves using iPS cells to develop oocytes for infertility treatments, a process known as the "DIOLs" technology. By introducing specific genes into these cells, Dioseve is able to produce oocytes quickly and cost-effectively, offering a new solution for couples struggling with fertility issues.
Assisted reproductive technology has remained largely unchanged for decades, with options limited and often dependent on individual circumstances. Dioseve's technology aims to provide a more accessible and flexible solution for those facing fertility challenges, giving them the freedom to choose when to start a family without the constraints of age or other factors.
Led by CEO Kazuma Kishida, Dioseve was established in 2021 and has quickly made a name for itself in the field of reproductive medicine. The company's commitment to innovation and accessibility has attracted a diverse group of investors, including ANRI, ASKA Pharmaceutical Co., DG Daiwa Ventures, Future Venture Capital Co., QR Investment, and others.
As Dioseve continues to grow and expand its reach, the company remains dedicated to revolutionizing the field of assisted reproductive technology, offering hope and new possibilities to those struggling to start a family.